N'oge na-adịbeghị anya, nnyocha nke Antengene's Phase I/II CLINCH nke ATG-022 (CLDN18.2 antibody-drug conjugate), onye agadi nwere ọrịa kansa afọ dị elu nke nwere ọtụtụ usoro chemotherapy, immunotherapy na ọgwụgwọ ezubere iche n'agbanyeghị nnukwu metastases nwetara nzaghachi zuru oke (CR) mgbe ATG-022 monotherapy gasịrị. PET/CT kwadoro ọnọdụ onye ọrịa ahụ enweghị kansa na Mee 2025.
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
ATG-022 bụ CLDN18.2 ADC nke Antengene chọtara ma mepụta n'ime ụlọ. Na ogbako ASCO GI 2025 na mbido afọ a, Antengene gosipụtara data ahụike emelitere maka ATG-022. N'ime ndị ọrịa nwere ngosipụta CLDN18.2 dị n'etiti ruo na elu (IHC 2+ ≥ 20%), ọnụego nzaghachi ebumnuche (ORR) bụ 42.9%, ọnụego njikwa ọrịa (DCR) bụ 95.2%. N'ime ndị ọrịa nwere ngosipụta CLDN18.2 dị ala (IHC 2+ < 20%), ORR bụ 30.0%, DCR bụkwa 50.0%. Data ndị a na-egosi na ATG-022 na-enye arụmọrụ dị mkpa na profaịlụ nchekwa dị mma n'ofe ọkwa ngosipụta CLDN18.2, gụnyere ngosipụta dị elu, dị ala, na ọbụna ngosipụta dị oke ala. Ọrụ ya nke na-egbochi etuto ahụ na-egosi na ATG-022 nwere ike inye ọtụtụ ndị ọrịa uru ọgwụgwọ ma e jiri ya tụnyere ọgwụgwọ ndị ọzọ e lekwasịrị anya na CLDN18.2. Ugbu a, ọmụmụ mmụba dose nke Usoro nke Abụọ nke ATG-022 na-aga n'ihu na mba China na Australia.
Mmezu a nke CR n'ime onye agadi a nwere ọrịa kansa afọ na-agba ume nke ukwuu, na-egosipụta ike ọgwụgwọ nke ATG-022 dị ka ọgwụgwọ ADC ọhụrụ. Ihe dị mkpa bụ na nke a abụghị naanị CR a hụrụ na nnyocha a na-aga n'ihu. Ruo ugbu a, a hụla ikpe CR atọ, gụnyere ndị ọrịa si mba China na Australia. Antengene na-atụ anya igosi data emelitere sitere na ọmụmụ ATG-022 na Nzukọ ESMO na-abịa na Ọktoba 2025.
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Oge ozi: Ọgọst-21-2025